Bioasis Technologies Inc BIOAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.02
- Bid/Ask
- $0.00 / $0.01
- Market Cap
- $476,484.09
- Volume/Avg
- 10,000 / 32,117
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.bioasis.us
Valuation
|
Metric
|
BIOAF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BIOAF
Financial Strength
|
Metric
|
BIOAF
|
|---|---|
Quick Ratio | 0.05 |
Current Ratio | 0.11 |
Interest Coverage | −2.04 |
Quick Ratio
BIOAF
Profitability
|
Metric
|
BIOAF
|
|---|---|
Return on Assets (Normalized) | −178.00% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BIOAF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lwzgrwkd | Thgg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ccmcvws | Kyldfk | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ggttwnbsd | Wrsmxdv | $98.8 Bil | |
MRNA
| Moderna Inc | Mhzkvxpt | Lcgdc | $38.8 Bil | |
ARGX
| argenx SE ADR | Cyzktnkm | Prv | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Tsspjjt | Tynk | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ksvcnksm | Rdttzk | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mthpvgt | Klhytsv | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dtzqkgvws | Wmkqkc | $12.4 Bil | |
INCY
| Incyte Corp | Xtxwqhb | Mwnzcbd | $11.9 Bil |